![赛琳生物制药(老挝)有限公司[官网]](/skin/img/logo.png){kind=logo}
Solid Preparation
Capmatinib
Capmatinib, used in the treatment of carrying MET exon 14 jumping mutation of patients with metastatic non-small-cell lung cancer (NSCLC), including first-line treatment (initial) patients with previously treated patients (governance).
Indications: for the patients with tumor
Specification: 250 mg * 56 grains
Unit: box
Retail price: $800
Note: Capmatinib used in the treatment of carrying MET exon 14 jumping mutation of metastatic non-small cell lung cancer (NSCLC) patients
Indications: for the patients with tumor
Specification: 250 mg * 56 grains
Unit: box
Retail price: $800
Note: Capmatinib used in the treatment of carrying MET exon 14 jumping mutation of metastatic non-small cell lung cancer (NSCLC) patients